Changes in intestinal microbiota and biochemical parameters in patients with inflammatory bowel disease and irritable bowel syndrome induced by the prolonged addition of soluble fibers to usual drug therapy

被引:0
|
作者
Watanabe, Hideo [1 ]
Inoue, Takahisa [2 ]
Miyamoto, Licht [3 ]
Ono, Yoshito [1 ]
Matsumoto, Kinya [1 ]
Takeda, Masanori [1 ]
Tsuchiya, Koichiro [2 ]
机构
[1] Watanabe Hosp, Matsuyama, Ehime, Japan
[2] Tokushima Univ, Grad Sch, Dept Med Pharmacol, 1-78-1 Sho Machi, Tokushima 7708505, Japan
[3] Kanagawa Inst Technol, Dept Nutr & Life Sci, Lab Pharmacol & Food Sci, Atsugi, Kanagawa, Japan
来源
JOURNAL OF MEDICAL INVESTIGATION | 2024年 / 71卷 / 1-2期
关键词
Partially hydrolyzed guar gum (PHGG); irritable bowel syndrome (IBS); Crohn's disease (CD); ulcerative colitis (UC); short-chain fatty acid-producing bacteria; HYDROLYZED GUAR GUM; C-REACTIVE PROTEIN; FECAL CALPROTECTIN; ULCERATIVE-COLITIS; CROHNS-DISEASE; ACTIVITY INDEX; LACTOFERRIN; NUTRITION; DIARRHEA;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objectives : Partially hydrolyzed guar gum (PHGG) is a soluble dietary fiber ; in addition to improving bowel movements, it maintains intestinal health by producing short-chain fatty acids. However, majority of clinical studies on PHGG have been concluded within a month and excluded usual drug therapy. Hence, this study aimed to determine the effects of long-term consumption of PHGG, in combination with drug therapy, on gut bacteria ratios, laboratory values for inflammatory response, and fecal characteristics. Methods and Results : The study was performed in patients with irritable bowel syndrome (IBS), Crohn's disease (CD), and ulcerative colitis (UC), by the administration of PHGG for six months while they continued their usual treatment. PHGG treatment caused significant changes in patients with IBS, including an increase in the abundance of short-chain fatty acid-producing bacteria, a significant decrease in Bacteroides abundance, and normalization of the Bristol scale of stool. In patients with UC, non-significant normalization of soft stools and decrease in fecal calprotectin were observed. Adverse events were not observed in any of the groups. Conclusion : Thus, it would be beneficial to include PHGG in the usual drug therapies of patients with IBS. J. Med. Invest. 71 : 121-128, February, 2024
引用
收藏
页码:121 / 128
页数:8
相关论文
共 37 条
  • [31] Gastrointestinal health: changes of intestinal mucosa and microbiota in patients with ulcerative colitis and irritable bowel syndrome from PM2.5-polluted regions of Ukraine
    Andrey Dorofeyev
    Anna Dorofeyeva
    Arsenii Borysov
    Ganna Tolstanova
    Tatiana Borisova
    Environmental Science and Pollution Research, 2023, 30 : 7312 - 7324
  • [32] Disruption of the pro-inflammatory, anti-inflammatory cytokines and tight junction proteins expression, associated with changes of the composition of the gut microbiota in patients with irritable bowel syndrome
    Ivashkin, V.
    Poluektov, Y.
    Kogan, E.
    Shifrin, O.
    Sheptulin, A.
    Kovaleva, A.
    Kurbatova, A.
    Krasnov, G.
    Poluektova, E.
    PLOS ONE, 2021, 16 (06):
  • [33] Gut microbiota changes are associated with type of advanced therapy in patients with Inflammatory Bowel Disease: baseline data from the Australian IBD Microbiome study
    Little, R.
    Jayawardana, T.
    Zhang, F.
    Koentgen, S.
    Wu, N.
    Tavakoli, P.
    Chung, A.
    Ho, A.
    Read, S.
    Boussioutas, A.
    Ward, M.
    Sparrow, M.
    Gibson, P.
    Ghaly, S.
    Corte, C.
    Talley, N.
    Leach, S.
    Lemberg, D.
    Dutt, S.
    Paramsothy, S.
    Leong, R.
    Connor, S.
    Hold, G.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i2413 - i2415
  • [34] Intestinal microbiota changes pre- and post-fecal microbiota transplantation for treatment of recurrent Clostridioides difficile infection among Iranian patients with concurrent inflammatory bowel disease
    Gholam-Mostafaei, Fahimeh Sadat
    Azimirad, Masoumeh
    Naseri, Kaveh
    Nabavi-Rad, Ali
    Asadzadeh Aghdaei, Hamid
    Shahrokh, Shabnam
    Ebrahimi Daryani, Nasser
    Yadegar, Abbas
    Zali, Mohammad Reza
    FRONTIERS IN MICROBIOLOGY, 2023, 14
  • [35] Prevalence of Irritable Bowel Syndrome Based on Rome IV Criteria in Patients in Biochemical and Endoscopic Remission From Newly Diagnosed Inflammatory Bowel Disease: One- and Three-Year Results (the IBSEN III Cohort)
    Olsen, Bjorn Christian
    Opheim, Randi
    Kristensen, Vendel A.
    Hoivik, Marte Lie
    Lund, Charlotte
    Aabrekk, Tone B.
    Johansen, Ingunn
    Holten, Kristina I. Aass
    Strande, Vibeke
    Glad, Ida Frivold
    Bengtson, May-Bente
    Ricanek, Petr
    Detlie, Trond Espen
    Medhus, Asle W.
    Boyar, Raziye
    Torp, Roald
    Vatn, Simen
    Frigstad, Svein Oskar
    Valeur, Jorgen
    Bernklev, Tomm
    Jelsness-Jorgensen, Lars-Petter
    Huppertz-Hauss, Gert
    INFLAMMATORY BOWEL DISEASES, 2025,
  • [36] De novo and drug-induced skin manifestations in Inflammatory Bowel Disease patients: The impact of anti-tumour necrosis factor therapy
    Zhao, H.
    Whitehead, E.
    Fitzgerald, A.
    Robertson, H.
    Turnbull, J.
    Sebastian, S.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1806 - I1806
  • [37] Effects of Spirulina (Arthrospira) platensis supplementation on intestinal permeability, antioxidant and inflammatory markers, quality of life and disease severity in patients with constipated-predominant irritable bowel syndrome: a randomized double‑blind, placebo‑controlled trial
    Saeede Jafari Nasab
    Awat Feizi
    Parisa Hajihashemi
    Mohammad-Hassan Entezari
    Manoj Sharma
    Peyman Adibi
    Mohammad Bagherniya
    Nutrition Journal, 24 (1)